Valuation: Tenax Therapeutics, Inc.

Market Cap 102M 87.3M 81.45M 74.74M 140M 9.76B 143M 966M 377M 4.89B 383M 375M 16.19B P/E 2026 *
-1.23x
P/E 2027 * -1.19x
Enterprise Value 16.76M 14.35M 13.39M 12.29M 23.09M 1.6B 23.54M 159M 61.92M 804M 62.94M 61.57M 2.66B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day-6.32%
1 week-2.73%
Current month-87.01%
1 month-88.65%
3 months-85.17%
6 months-85.48%
Current year-85.40%
1 week 1.59
Extreme 1.59
1.96
1 month 1.31
Extreme 1.31
16.5
Current year 1.31
Extreme 1.31
19.4
1 year 1.31
Extreme 1.31
19.4
3 years 1.31
Extreme 1.31
61.2
5 years 1.31
Extreme 1.31
3,135.04
10 years 1.31
Extreme 1.31
84,800
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 69 25/02/2021
Date Insider Type Main position Quantity % Market Cap.
13/7/26 Fiscal year

Chief Executive Officer

17,438 0.0657%
11/5/26 Free

Chief Financial Officer

460,000 2.6748%
30/1/26 Other

Controller/Auditor

50,000 0.8008%
Change 5-day change 1-year change 3-year change Capi.($)
-6.32%-2.73%-70.23%-93.90% 102M
-0.24%+3.95%+3.14%+24.45% 51.22B
-1.36%+4.82%+485.55%+614.84% 45.38B
-2.04%+3.69%+19.34%+91.23% 41.97B
+2.72%+6.02%+33.33%+19.66% 42.15B
0.00%-3.91%+18.49%+47.98% 31.95B
-1.85%+3.48% - - 16.73B
+0.72%+5.27%+31.55%+145.37% 17.1B
-0.66%+2.64%+6.32%+34.49% 14.76B
+0.50%+3.62%+82.64%+46.53% 13.91B
Average -0.86%+2.64%+67.79%+103.40% 27.53B
Weighted average by Cap. -0.25%+3.18%+103.57%+150.76%

Financials

2026 *2027 *
Net sales - -
Net income -72.73M -62.28M -58.1M -53.32M -100M -6.96B -102M -689M -269M -3.49B -273M -267M -11.55B -84.06M -71.97M -67.15M -61.62M -116M -8.04B -118M -797M -311M -4.03B -316M -309M -13.35B
Net Debt -85.2M -72.95M -68.06M -62.45M -117M -8.15B -120M -807M -315M -4.09B -320M -313M -13.53B -10.2M -8.73M -8.15M -7.48M -14.05M -976M -14.33M -96.66M -37.68M -489M -38.3M -37.47M -1.62B
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
20/08/26 US$1.780 -6.32% 4,098,957
19/08/26 US$1.900 +11.76% 11,930,769
18/08/26 US$1.700 -0.58% 13,374,333
17/08/26 US$1.710 -5.00% 9,893,997
14/08/26 US$1.800 -1.64% 5,842,424
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1.780USD
Average target price
11.70USD
Spread / Average Target
+557.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock